Small biotech firms struggle to navigate Trump tariffs, seek exemptions

Smaller biotech companies are facing uncertainty over how to obtain exemptions from new US import tariffs imposed under the Trump administration. The lack of clear guidance is disrupting supply chains and raising costs for the sector. The impact is uneven, with larger firms better positioned to absorb the tariffs.